Publications & Reports

Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action.

Creek DJ, Chua HH, Cobbold SA, Nijagal B, Macrae JI, Dickerman BK, Gilson PR, Ralph SA, McConville MJ
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052, Australia darren.creek@monash.edu.

Abstract

High-throughput phenotypic screening of chemical libraries has resulted in the identification of thousands of compounds with potent antimalarial activity, although in most cases, the mechanism(s) of action of these compounds remain unknown. Here we have investigated the mode of action of 90 antimalarial compounds derived from the Malaria Box collection using high-coverage, untargeted metabolomics analysis. Approximately half of the tested compounds induced significant metabolic perturbations in in vitro cultures of P. falciparum In most cases, the metabolic profiles were highly correlated with known antimalarials, in particular artemisinin, the 4-aminoquinolines, or atovaquone. Select Malaria Box compounds also induced changes in intermediates in essential metabolic pathways such as isoprenoid biosynthesis (i.e. 2-C-methyl-D-erythritol 2,4-cyclodiphosphate), and linolenic acid metabolism (i.e. traumatic acid). This study provides a comprehensive database of the metabolic perturbations induced by chemically diverse inhibitors and highlights the utility of metabolomics for triaging new lead compounds and defining specific modes of action, which will assist with the development and optimization of new antimalarial drugs.

Link to publisher’s web site

Publication

  • Journal: Antimicrobial Agents and Chemotherapy
  • Published: 21/10/2016
  • Volume: 60
  • Issue: 11
  • Pagination: 6650-6663

Author

Health Issue

Download